retatrutide phase 2 trial obesity VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide Phase 2: Type 2

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults with type 2 diabetes

Compared with DPP-4 inhibitors, the lower rate of hyperkalemia was consistently observed across individual agents in the SGLT-2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) and GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide, semaglutide) classes

For tinnitus associated with Ozempic (semaglutide), discontinuation of the medication should be considered as the first-line management approach, followed by...

Convenient in-person clinics.

Safety & Precautions